OR WAIT null SECS
© 2022 MJH Life Sciences and Consultant Live. All rights reserved.
August 03, 2022
Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.
An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.
August 01, 2022
Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.
Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.